Nimble Announces Formation of a World-Class Scientific Advisory Board
Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.
- Nimble Therapeutics today announced the formation of the Nimble Scientific Advisory Board (SAB) to support the company’s mission to create orally delivered peptide therapeutics to treat immune-mediated diseases.
- “We are honored to have these extraordinary scientific leaders join Nimble in its mission to create oral therapeutics to treat patients with immune-mediated diseases,” said Pete Gough, CSO of Nimble Therapeutics.
- Luisa is a member of the Scientific Advisory Board of Anaptys, GPCR, Imimidomics and Attovia, and was previously on the SAB of Prometheus, Ambrx and Ventyx Bio and on the Board of Directors of Jounce Therapeutics.
- Previously, Tomi was a Distinguished Scientist at Merck & Company, Founding Chief Scientific Officer at Aileron Therapeutics and Senior Vice-President of Drug Discovery at Ariad Pharmaceuticals (now Takeda).